Dow Jones

38,686.32

1.51%

Regístrate gratis para obtener cotizaciones en tiempo real, gráficos interactivos, flujo de opciones en vivo y más.

Regístrate

Inicio
Invertir
Acciones
Estados Unidos
NASDAQ
Armo Biosciences, Inc. (delisted) (ARMO)
Armo Biosciences, Inc. (delisted) (ARMO) Noticias

ARMO

Armo Biosciences, Inc. (delisted) (ARMO)

Armo Biosciences, Inc. (delisted)

Fecha:

Regulatory News

Text Search:

Ordernar por:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:ARMO

Fecha	Hora	Fuente	Título	Símbolo	Compañía
17/01/2019	03:00	PR Newswire (US)	Asceneuron Appoints Peter Van Vlasselaer as Chairman	NASDAQ:ARMO	Armo Biosciences, Inc. (delisted)
02/07/2018	15:49	Edgar (US Regulatory)	Termination of Registration of a Class of Security Under Section 12(b) (15-12b)	NASDAQ:ARMO	Armo Biosciences, Inc. (delisted)
22/06/2018	18:35	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	NASDAQ:ARMO	Armo Biosciences, Inc. (delisted)
22/06/2018	08:13	Edgar (US Regulatory)	(25-NSE)	NASDAQ:ARMO	Armo Biosciences, Inc. (delisted)
22/06/2018	08:03	Edgar (US Regulatory)	Post-effective Amendment to an S-8 Filing (s-8 Pos)	NASDAQ:ARMO	Armo Biosciences, Inc. (delisted)
22/06/2018	07:59	Edgar (US Regulatory)	Current Report Filing (8-k)	NASDAQ:ARMO	Armo Biosciences, Inc. (delisted)
22/06/2018	07:54	Edgar (US Regulatory)	Amended Statement of Ownership: Solicitation (sc 14d9/a)	NASDAQ:ARMO	Armo Biosciences, Inc. (delisted)
22/06/2018	07:48	Edgar (US Regulatory)	Amended Tender Offer Statement by Third Party (sc To-t/a)	NASDAQ:ARMO	Armo Biosciences, Inc. (delisted)
22/06/2018	07:31	PR Newswire (US)	Lilly Completes Acquisition of ARMO BioSciences	NASDAQ:ARMO	Armo Biosciences, Inc. (delisted)
23/05/2018	08:18	Edgar (US Regulatory)	Statement of Ownership: Solicitation (sc 14d9)	NASDAQ:ARMO	Armo Biosciences, Inc. (delisted)
23/05/2018	07:49	Edgar (US Regulatory)	Tender Offer Statement by Third Party (sc To-t)	NASDAQ:ARMO	Armo Biosciences, Inc. (delisted)
15/05/2018	15:52	Edgar (US Regulatory)	Quarterly Report (10-q)	NASDAQ:ARMO	Armo Biosciences, Inc. (delisted)
14/05/2018	10:38	PR Newswire (US)	WeissLaw LLP: ARMO BioSciences Inc. Acquisition May Not Be In The Best Interests of ARMO shareholders	NASDAQ:ARMO	Armo Biosciences, Inc. (delisted)
10/05/2018	16:03	Dow Jones News	Health Care Up Amid Deal Activity -- Health Care Roundup	NASDAQ:ARMO	Armo Biosciences, Inc. (delisted)
10/05/2018	15:43	Edgar (US Regulatory)	Written Communication by the Subject Company Relating to a Third Party Tender Offer (sc14d9c)	NASDAQ:ARMO	Armo Biosciences, Inc. (delisted)
10/05/2018	10:57	PR Newswire (US)	ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of ARMO BioSciences, Inc.	NASDAQ:ARMO	Armo Biosciences, Inc. (delisted)
10/05/2018	08:16	Dow Jones News	Eli Lilly Buys Immunotherapy Cancer Treatment Company for $1.6 Billion	NASDAQ:ARMO	Armo Biosciences, Inc. (delisted)
10/05/2018	07:41	PR Newswire (US)	ARMO BioSciences Alert: Johnson Fistel Investigates Proposed Sale of ARMO BioSciences, Inc.; Is $50 a Fair Price?	NASDAQ:ARMO	Armo Biosciences, Inc. (delisted)
10/05/2018	07:05	Edgar (US Regulatory)	Written Communication Relating to an Issuer or Third Party (sc To-c)	NASDAQ:ARMO	Armo Biosciences, Inc. (delisted)
10/05/2018	06:30	PR Newswire (US)	Lilly Announces Agreement To Acquire ARMO BioSciences	NASDAQ:ARMO	Armo Biosciences, Inc. (delisted)
25/04/2018	15:18	GlobeNewswire Inc.	ARMO BioSciences Announces Poster Presentations of Pegilodecakin (AM0010) at the 2018 American Society of Clinical Oncology (...	NASDAQ:ARMO	Armo Biosciences, Inc. (delisted)
03/04/2018	07:00	GlobeNewswire Inc.	ARMO BioSciences to Participate in Panel on Cytokines at 8th Annual Cancer Immunotherapy Conference	NASDAQ:ARMO	Armo Biosciences, Inc. (delisted)
02/04/2018	07:00	GlobeNewswire Inc.	ARMO BioSciences Reports FY 2017 Financial Results	NASDAQ:ARMO	Armo Biosciences, Inc. (delisted)
30/03/2018	15:48	Edgar (US Regulatory)	Annual Report (10-k)	NASDAQ:ARMO	Armo Biosciences, Inc. (delisted)
29/03/2018	07:00	GlobeNewswire Inc.	ARMO BioSciences Enrolls First Patient in the CYPRESS 2 Trial Evaluating AM0010 in Non-Small Cell Lung Cancer	NASDAQ:ARMO	Armo Biosciences, Inc. (delisted)
26/03/2018	07:00	GlobeNewswire Inc.	ARMO BioSciences Announces Positive Outcome of First Interim Analysis in SEQUOIA Phase 3 Pancreatic Cancer Study	NASDAQ:ARMO	Armo Biosciences, Inc. (delisted)
16/03/2018	16:16	Edgar (US Regulatory)	Statement of Ownership (sc 13g)	NASDAQ:ARMO	Armo Biosciences, Inc. (delisted)
12/02/2018	09:24	GlobeNewswire Inc.	ARMO BioSciences, Inc. (Nasdaq: ARMO) to Ring The Nasdaq Stock Market Closing Bell	NASDAQ:ARMO	Armo Biosciences, Inc. (delisted)
25/01/2018	20:09	PR Newswire (US)	ARMO BioSciences Announces Pricing of Initial Public Offering	NASDAQ:ARMO	Armo Biosciences, Inc. (delisted)